Journal profile · ONCOLOGY
Translational Oncology
ISSN 1944-7124 · eISSN 1936-5233 · Neoplasia Press · UNITED STATES
Translational Oncology: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 4.9; fully open access; APC about USD 3,880; median 80 days to acceptance (96 articles, last 24 months); community-reported acceptance: fairly easy; 378 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Translational Oncology is published by Neoplasia Press and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Ferroptosis and cancer prognosis, Cancer Immunotherapy and Biomarkers and Cancer Cells and Metastasis, together about 24.4% of its articles. Its main subfields are Cancer Research. (generated from OpenAlex topic counts and CAS ranking data)
Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials. Translational Oncology does not accept Case Reports.
From the journal's Aims & Scope
Research area (LetPub): ONCOLOGY
Editor-in-chief Mohammad AsimPublisher website
Editorial board by country: 59 in mainland China (about 10%); most named United States 212, Mainland China 59, Italy 51, India 38, Germany 17 (566 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Ferroptosis and cancer prognosisMedicine9.4%
- Cancer Immunotherapy and BiomarkersMedicine9.1%
- Cancer Cells and MetastasisMedicine5.9%
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology5.5%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology5.4%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology4.8%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology4.8%
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology4.5%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.9LetPub ·
- Impact factor (publisher)
- 4.9Publisher website ·
- CiteScore 2026-06
- 7.3LetPub ·
- CiteScore (publisher)
- 7.3Publisher website ·
- SJR 2026-06
- 1.38LetPub ·
- SNIP 2026-06
- 0.91LetPub ·
- h-index
- 39LetPub ·
- h-index
- 97OpenAlex ·
- i10-index
- 1,768OpenAlex ·
- 2-year mean citedness
- 4.24OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 359LetPub ·
Articles by year OpenAlex count · 3,347 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 402 | 402 | 157 |
| 2025 | 378 | 378 | 1,298 |
| 2024 | 396 | 396 | 3,530 |
| 2023 | 241 | 241 | 3,611 |
| 2022 | 272 | 272 | 4,904 |
| 2021 | 321 | 321 | 9,936 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
80 daysMedian, submission to acceptance · P25–P75 63 days – 123 days
- Acceptance to online
- median 9 days (96 articles)
- Submission to online
- median 90 days
- Sample
- 96 articles with submission and acceptance dates (963 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- Fairly easyLetPub ·
- Submission to first decision
- 22 daysPublisher website ·
- First decision after review
- 92 daysPublisher website ·
- Submission to acceptance
- 150 daysPublisher website ·
- Acceptance to publication
- 7 daysPublisher website ·
- Submission to publication (journal-reported)
- about 22 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,880 | Yes | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 3,390 / EUR 3,170 / GBP 2,710 / JPY 420,460 | — | — | |
| LetPub | USD 2,930 | Yes | — | |
| Publisher website | USD 3,960 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers3, by deadline
- Emerging Insights into the Tumor Immune Microenvironment: Mechanisms, Biomarkers, and Therapeutic TargetsDeadline
- Advances in Translational Oncology: Integrating Tumor Microenvironment, Biomarkers, and Therapeutic StrategiesDeadline
- Systemic Inflammation-Metabolism Dysregulation and Cancer: From Fundamental Mechanisms to Precision Therapeutic InterventionsDeadline
What to prepare5 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
- Manuscript length
- ≤ 4,500 words
- Reference style
- Author–date
- Cover letter
- Required
Article types accepted17, with length limits
- commentariesCommentaries are short articles that highlight one or several research papers published in a recent issue of the Journal, placing the results in context for the…Length not stated
- commentaryibutions are not considered. Mechanics: Commentaries have a limit of 1,500 words and no more than 10 references. Authors are asked to limitmain text ≤ 1,500 words · references ≤ 10
- editorialsEditorials serve as the voice of Translational Oncology and are written by the Journal's Editors and Guest Editors.Length not stated
- lettercted and invited to respond. Mechanics: Letters have a limit of 1,000 words and no more than 10 references. Authors are asked to limitmain text ≤ 1,000 words · references ≤ 10
- letters to the editorTranslational Oncology publishes material in the form of original articles, review articles, opinions, short communications such as spotlights, previews and per…Length not stated
- letters to the editorsLetters to the Editors which comment directly on work that has previously been published in the Journal will be considered.Length not stated
- opinionTranslational Oncology publishes material in the form of original articles, review articles, opinions, short communications such as spotlights, previews and per…main text ≤ 2,500 words · references ≤ 60
- opinion articleOpinions may reflect an individual perception, involvement, or contribution to oncology, and should be prepared in a similar way to a Review.Length not stated
- original articleTranslational Oncology publishes material in the form of original articles, review articles, opinions, short communications such as spotlights, previews and per…Length not stated
- original research articleTranslational Oncology publishes material in the form of original articles, review articles, opinions, short communications such as spotlights, previews and per…main text ≤ 4,500 words
- perspectiveTranslational Oncology publishes material in the form of original articles, review articles, opinions, short communications such as spotlights, previews and per…main text ≤ 1,200 words · references ≤ 10
- perspectivesPerspectives are short pieces that aim to highlight for a very broad audience a significant recent development in the field or to raise awareness about a topic …Length not stated
- research articleTranslational Oncology publishes material in the form of original articles, review articles, opinions, short communications such as spotlights, previews and per…Length not stated
- reviewTranslational Oncology publishes material in the form of original articles, review articles, opinions, short communications such as spotlights, previews and per…main text ≤ 4,500 words
- review articleTranslational Oncology publishes material in the form of original articles, review articles, opinions, short communications such as spotlights, previews and per…main text ≤ 4,500 words · references ≤ 80
- short communicationTranslational Oncology publishes material in the form of original articles, review articles, opinions, short communications such as spotlights, previews and per…Length not stated
- spotlightsSpotlights are short articles intended to provide a quick update on one or two recent research articles published in other journals that signify a major advance…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing allowed Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Neoplasia Press
- Country or region
- UNITED STATES
- Language
- English
- ISSN
- 1944-7124
- Electronic ISSN
- 1936-5233
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Translational Oncology
What CAS zone is Translational Oncology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Translational Oncology is in Zone 3 of Medicine, and in Zone 3 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Translational Oncology?
The latest impact factor listed by LetPub is 4.9; CiteScore 7.3, h-index 97.
How long does peer review take at Translational Oncology?
Based on the dates recorded on 96 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 80 days (interquartile range 63–123 days); authors report an average review time of 6–12 weeks; the community-reported acceptance is “Fairly easy”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Translational Oncology?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7; Manuscript length: ≤ 4,500 words; Reference style: Author–date; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Translational Oncology based?
Of the 566 board members whose country the journal's board page names, 59 (about 10%) are in mainland China; the countries named most often are United States (212), Mainland China (59) and Italy (51). Counted from the institutions listed on the board page; for reference only.
Which databases index Translational Oncology?
According to LetPub and DOAJ records, Translational Oncology is indexed in SCIE, Scopus and DOAJ.
Is Translational Oncology open access, and what is the APC?
Translational Oncology is a fully open-access journal. APC about USD 3,880.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .